KPV peptide

KPV is a tripeptide, three amino acids long (lysine, proline, valine). It is the last three amino acids of alpha-melanocyte-stimulating hormone (alpha-MSH), a hormone with known anti-inflammatory effects, and a 2007 review attributed most of alpha-MSH's anti-inflammatory activity to this C-terminal fragment [2]. Unlike full-length alpha-MSH, KPV is not marketed for tanning or appetite; it is sold for gut and skin inflammation.

All of the published evidence for KPV comes from cell cultures and mice. We searched PubMed for a human clinical trial of KPV and found none. Under a draft HHS enforcement policy announced October 28, 2026, HHS says it does not intend to take action against licensed 503A pharmacies and physicians that compound KPV under ten conditions, limited to topical and oral forms [1]. That makes a prescribed, pharmacy-made KPV possible in the US. It does not add any human evidence that KPV works.

KPV is not FDA-approved for any use. On October 28, 2026, HHS announced a draft, interim enforcement-discretion policy, which is not final and not binding on HHS or the public (comments are open until November 13, 2026): while FDA decides through rulemaking whether KPV belongs on the 503A bulk drug substances list, HHS does not intend to take action against a State-licensed pharmacy, Federal facility, or licensed physician that compounds KPV acetate when ten conditions are all met [1]. The policy document itself states that compounded drugs are not FDA-approved and that FDA does not review their safety, effectiveness, or quality.

Route limits: the policy covers KPV acetate in topical and oral dosage forms only [1]. Injectable KPV is outside it. For any oral peptide product, the compounder is expected to keep documentation that the specific formulation reaches adequate oral bioavailability in humans [1].

The other conditions include a patient-specific prescription; bulk peptide from an FDA-registered manufacturer with a certificate of analysis covering identity, purity, potency, endotoxin, heavy metals, microbial limits and impurities; a single active ingredient per product (no KPV blends); the label statement "This is a compounded drug product. Not for resale."; and reporting of serious adverse events and quality problems to FDA MedWatch and the states [1]. HHS says it may revisit the policy if a safety signal or quality problem appears.

History: KPV (free base) and KPV acetate sat in FDA's Category 2 from September 2023 until April 22, 2026. FDA's drug center (CDER) recommended against listing it, and the Pharmacy Compounding Advisory Committee voted in favor [1]. HHS's stated reasons for including it were documented use, an improved quality record for the acetate form, and its view that CDER's safety conclusion reflected missing information rather than an observed harm [1]. An independent analysis of the advisory committee review is available in the compounding trade literature [7].

In human intestinal and immune cell lines, nanomolar concentrations of KPV blocked activation of NF-kappaB and MAP kinase signaling and reduced inflammatory cytokine release. The same study found that KPV enters cells through PepT1, a transporter for small dietary peptides that is normally found in the small intestine and is switched on in the inflamed colon [3]. That transporter is the main reason KPV is discussed as an oral peptide, which is unusual: most peptides are broken down in the gut.

Alpha-MSH acts largely through the melanocortin-1 receptor. KPV's effect in one mouse study persisted in animals with a non-functional version of that receptor, which suggests KPV works at least partly through a different route [4]. Reviews of the melanocortin system in inflammatory bowel disease treat KPV as one of several candidate molecules, with the supporting data drawn from mouse colitis models [6].

The gut evidence is entirely in mice. In two chemically induced colitis models, KPV added to drinking water reduced colitis and inflammatory cytokine expression [3]. A second group tested KPV in two colitis models and reported earlier recovery, stronger regain of body weight, less inflammatory infiltrate, and lower myeloperoxidase activity; in mice lacking a working melanocortin-1 receptor, KPV treatment kept every treated animal alive through DSS colitis [4]. A later study packaged KPV in hyaluronic-acid nanoparticles and found the oral nanoparticle form protected the colon lining better than a comparison KPV formulation in a mouse ulcerative colitis model [5].

The skin and topical case is even thinner. The anti-inflammatory effects of alpha-MSH have been shown in animal models of contact dermatitis, vasculitis, asthma, colitis and arthritis, and that review credits most of the activity to the KPV fragment [2], but we found no published study of a topical KPV product in people.

Evidence grade: D. There is no human trial of KPV for inflammatory bowel disease, leaky gut, skin conditions, or anything else. The mouse results are consistent and come from more than one group, which is better than many research peptides manage, but mouse colitis is a model, and the history of inflammatory bowel disease drugs includes many compounds that worked in mice and failed in people.

There is no established human dose of KPV by any route, because no human study has been published. The mouse studies gave KPV in drinking water or in nanoparticles, and those amounts do not translate to a human dose. We do not publish a protocol. If a clinician prescribes compounded KPV under the HHS policy, the product will be topical or oral, and the strength and schedule are the prescriber's decision, not something an evidence base supports.

Human safety data for KPV do not exist in the published literature. FDA's earlier review recorded no human exposure data by any route, and HHS's own explanation for including KPV describes CDER's concern as an absence of information rather than an observed harm [1]. Both statements mean the same thing for a patient: nobody knows the side-effect profile.

The practical risk differs by source. Research-chemical KPV sold online "for research use only" has no verified identity, purity, or sterility. A KPV product compounded under the HHS policy must come from a registered manufacturer with a lot-level certificate of analysis, contain KPV alone, and be reported to MedWatch if a serious adverse event occurs [1]. That is a real quality difference. It is not evidence of effectiveness.